The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) will support Wave Life Sciences Ltd's (NASDAQ:WVE) amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) program.
- The organizations will support the Company's FOCUS-C9 Phase 1b/2a trial of WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD) and amyotrophic lateral sclerosis (C9-ALS).
- The partnership provides an investment from ADDF and AFTD to support the evaluation of fluid biomarkers, functional assessments, and digital biomarkers.
- Also See: Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs.
- WVE-004 is a stereopure antisense oligonucleotide designed to selectively target transcriptional variants containing a hexanucleotide repeat expansion (G4C2) associated with the C9orf72 gene sparing C9orf72 protein.
- G4C2 expansions in C9orf72 are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD.
- Price Action: WVE shares closed at $2.15 on Tuesday.
